#108281
#108282
Re: Farmas USA
#108283
Re: Farmas USA
Bernstein upgraded Celgene (NASDAQ: CELG) from Market Perform to Outperform, price target $102.00 (from $121.00)
#108284
Re: Farmas USA
Futuros cercanos a -1%
#108285
Re: Farmas USA
ESPR halted pending news
Met primary endpoint
https://finance.yahoo.com/news/esperion-announces-third-pivotal-phase-121500518.html?.tsrc=applewf&guccounter=1
#108286
Re: Farmas USA
MRK
KEYTRUDA® Significantly Improved OS and PFS as First-Line Treatment for Squamous Non-Small Cell Lung Cancer in Pivotal Phase 3 KEYNOTE-407 Trial
#108287
Re: Farmas USA
#108288